- About Us
- Clinical Trials
- News & Publications
- Business Development
SOTIO starts Phase I/II trial of DCVAC in combination with ONCOS-102: the Targovax adenovirus based immunotherapy
SOTIO, a biotechnology company owned by the PPF Group, announces today that the first patient was enrolled to the SP015 clinical trial of a combination of DCVAC/PCa, an active cellular immunotherapy, and ONCOS-102, an immune-priming engineered human serotype 5 adenovirus, for patients with prostate cancer. The trial is planned for the United Kingdom and the Czech Republic. SOTIO is collaborating with Targovax,a clinical stage immuno-oncology company developing ONCOS-102.
SOTIO completes enrollment of phase III VIABLE study in late stage prostate cancer
SOTIO, a biotechnology company owned by the PPF Group, today announced the enrollment of the last patient into the VIABLE study, a global Phase III clinical trial evaluating DCVAC/PCa in combination with docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC).
SOTIO exhibits at ESMO 2015
SOTIO is presenting its clinical research program at the European Society for Medical Oncology’s European Cancer Congress 2015 in Vienna (ESMO 2015). SOTIO’s exhibit can be found at booth no.1107 in ESMO Exhibition Hall B. Over the course of the ESMO Congress, SOTIO’s representatives will meet with important key opinion leaders (KOLs), researchers participating in company clinical trials and other medical and clinical experts.